Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival

Anne J Novak, Jaime R. Darce, Bonnie K. Arendt, Brandon Harder, Kathy Henderson, Wayne Kindsvogel, Jane A. Gross, Philip R. Greipp, Diane F Jelinek

Research output: Contribution to journalArticle

308 Citations (Scopus)

Abstract

Multiple myeloma (MM) is a progressive disease that is thought to result from multiple genetic insults to the precursor plasma cell that ultimately affords the tumor cell with proliferative potential despite its differentiated phenotype and resistance to undergoing apoptosis. Altered expression of antiapoptotic factors as well as growth factors have been described in a significant number of patients. However, the key regulatory elements that control myeloma development and progression remain largely undefined. Because of the knowledge that B-lymphocyte stimulator (BLyS), a tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B-cell development and homeostasis, promotes the survival of malignant B cells, we began a coordinated study of BLyS and its receptors in MM. All MM cells studied expressed one or more of 3 known receptors (B-cell maturation antigen [BCMA], transmembrane activator and CAML interactor [TACI], and B-cell activating factor receptor [BAFF-R]) for BLyS; however, the pattern of expression was variable. Additionally, we provide evidence that BLyS can modulate the proliferative capacity and survival of MM cells. Finally, we provide evidence that BLyS is expressed by MM cells and is present in the bone marrow of patients with MM. Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications because they may be potential therapeutic targets.

Original languageEnglish (US)
Pages (from-to)689-694
Number of pages6
JournalBlood
Volume103
Issue number2
DOIs
StatePublished - Jan 15 2004

Fingerprint

B-Cell Maturation Antigen
B-Cell Activating Factor
Multiple Myeloma
Survival
Growth
Cells
Interleukin-4 Receptors
B-Lymphocytes
Cell growth
Aptitude
Tumors
Intercellular Signaling Peptides and Proteins
Bone
Tumor Necrosis Factor-alpha
Plasma Cells
Apoptosis
Plasmas
Cell Survival
Homeostasis
Bone Marrow

ASJC Scopus subject areas

  • Hematology

Cite this

Expression of BCMA, TACI, and BAFF-R in multiple myeloma : A mechanism for growth and survival. / Novak, Anne J; Darce, Jaime R.; Arendt, Bonnie K.; Harder, Brandon; Henderson, Kathy; Kindsvogel, Wayne; Gross, Jane A.; Greipp, Philip R.; Jelinek, Diane F.

In: Blood, Vol. 103, No. 2, 15.01.2004, p. 689-694.

Research output: Contribution to journalArticle

Novak, AJ, Darce, JR, Arendt, BK, Harder, B, Henderson, K, Kindsvogel, W, Gross, JA, Greipp, PR & Jelinek, DF 2004, 'Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival', Blood, vol. 103, no. 2, pp. 689-694. https://doi.org/10.1182/blood-2003-06-2043
Novak, Anne J ; Darce, Jaime R. ; Arendt, Bonnie K. ; Harder, Brandon ; Henderson, Kathy ; Kindsvogel, Wayne ; Gross, Jane A. ; Greipp, Philip R. ; Jelinek, Diane F. / Expression of BCMA, TACI, and BAFF-R in multiple myeloma : A mechanism for growth and survival. In: Blood. 2004 ; Vol. 103, No. 2. pp. 689-694.
@article{f175b4c1e25f49999eb56807763ae2d1,
title = "Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival",
abstract = "Multiple myeloma (MM) is a progressive disease that is thought to result from multiple genetic insults to the precursor plasma cell that ultimately affords the tumor cell with proliferative potential despite its differentiated phenotype and resistance to undergoing apoptosis. Altered expression of antiapoptotic factors as well as growth factors have been described in a significant number of patients. However, the key regulatory elements that control myeloma development and progression remain largely undefined. Because of the knowledge that B-lymphocyte stimulator (BLyS), a tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B-cell development and homeostasis, promotes the survival of malignant B cells, we began a coordinated study of BLyS and its receptors in MM. All MM cells studied expressed one or more of 3 known receptors (B-cell maturation antigen [BCMA], transmembrane activator and CAML interactor [TACI], and B-cell activating factor receptor [BAFF-R]) for BLyS; however, the pattern of expression was variable. Additionally, we provide evidence that BLyS can modulate the proliferative capacity and survival of MM cells. Finally, we provide evidence that BLyS is expressed by MM cells and is present in the bone marrow of patients with MM. Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications because they may be potential therapeutic targets.",
author = "Novak, {Anne J} and Darce, {Jaime R.} and Arendt, {Bonnie K.} and Brandon Harder and Kathy Henderson and Wayne Kindsvogel and Gross, {Jane A.} and Greipp, {Philip R.} and Jelinek, {Diane F}",
year = "2004",
month = "1",
day = "15",
doi = "10.1182/blood-2003-06-2043",
language = "English (US)",
volume = "103",
pages = "689--694",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Expression of BCMA, TACI, and BAFF-R in multiple myeloma

T2 - A mechanism for growth and survival

AU - Novak, Anne J

AU - Darce, Jaime R.

AU - Arendt, Bonnie K.

AU - Harder, Brandon

AU - Henderson, Kathy

AU - Kindsvogel, Wayne

AU - Gross, Jane A.

AU - Greipp, Philip R.

AU - Jelinek, Diane F

PY - 2004/1/15

Y1 - 2004/1/15

N2 - Multiple myeloma (MM) is a progressive disease that is thought to result from multiple genetic insults to the precursor plasma cell that ultimately affords the tumor cell with proliferative potential despite its differentiated phenotype and resistance to undergoing apoptosis. Altered expression of antiapoptotic factors as well as growth factors have been described in a significant number of patients. However, the key regulatory elements that control myeloma development and progression remain largely undefined. Because of the knowledge that B-lymphocyte stimulator (BLyS), a tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B-cell development and homeostasis, promotes the survival of malignant B cells, we began a coordinated study of BLyS and its receptors in MM. All MM cells studied expressed one or more of 3 known receptors (B-cell maturation antigen [BCMA], transmembrane activator and CAML interactor [TACI], and B-cell activating factor receptor [BAFF-R]) for BLyS; however, the pattern of expression was variable. Additionally, we provide evidence that BLyS can modulate the proliferative capacity and survival of MM cells. Finally, we provide evidence that BLyS is expressed by MM cells and is present in the bone marrow of patients with MM. Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications because they may be potential therapeutic targets.

AB - Multiple myeloma (MM) is a progressive disease that is thought to result from multiple genetic insults to the precursor plasma cell that ultimately affords the tumor cell with proliferative potential despite its differentiated phenotype and resistance to undergoing apoptosis. Altered expression of antiapoptotic factors as well as growth factors have been described in a significant number of patients. However, the key regulatory elements that control myeloma development and progression remain largely undefined. Because of the knowledge that B-lymphocyte stimulator (BLyS), a tumor necrosis factor (TNF) family member shown to be critical for maintenance of normal B-cell development and homeostasis, promotes the survival of malignant B cells, we began a coordinated study of BLyS and its receptors in MM. All MM cells studied expressed one or more of 3 known receptors (B-cell maturation antigen [BCMA], transmembrane activator and CAML interactor [TACI], and B-cell activating factor receptor [BAFF-R]) for BLyS; however, the pattern of expression was variable. Additionally, we provide evidence that BLyS can modulate the proliferative capacity and survival of MM cells. Finally, we provide evidence that BLyS is expressed by MM cells and is present in the bone marrow of patients with MM. Expression of BCMA, TACI, and BAFF-R by MM taken together with the ability of BLyS to support MM cell growth and survival has exciting implications because they may be potential therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=0942298590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0942298590&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-06-2043

DO - 10.1182/blood-2003-06-2043

M3 - Article

C2 - 14512299

AN - SCOPUS:0942298590

VL - 103

SP - 689

EP - 694

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -